1. Home
  2. FAST vs INSM Comparison

FAST vs INSM Comparison

Compare FAST & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fastenal Company

FAST

Fastenal Company

HOLD

Current Price

$41.68

Market Cap

46.4B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$205.86

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAST
INSM
Founded
1967
1988
Country
United States
United States
Employees
N/A
N/A
Industry
RETAIL: Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.4B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
FAST
INSM
Price
$41.68
$205.86
Analyst Decision
Hold
Strong Buy
Analyst Count
10
19
Target Price
$44.61
$178.71
AVG Volume (30 Days)
6.6M
2.7M
Earning Date
01-16-2026
10-30-2025
Dividend Yield
2.11%
N/A
EPS Growth
6.38
N/A
EPS
1.07
N/A
Revenue
$7,997,600,000.00
$447,022,000.00
Revenue This Year
$10.88
$43.10
Revenue Next Year
$8.98
$128.25
P/E Ratio
$39.06
N/A
Revenue Growth
6.92
30.34
52 Week Low
$35.31
$60.40
52 Week High
$50.63
$212.75

Technical Indicators

Market Signals
Indicator
FAST
INSM
Relative Strength Index (RSI) 55.94 63.41
Support Level $39.81 $202.27
Resistance Level $40.70 $212.75
Average True Range (ATR) 0.74 6.77
MACD 0.35 -0.89
Stochastic Oscillator 88.75 70.56

Price Performance

Historical Comparison
FAST
INSM

About FAST Fastenal Company

Fastenal began as an industrial retailer, expanding its product portfolio from nuts and bolts to cutting tools, safety equipment, and janitorial supplies. It transitioned into a distributor by building out a dense network of branches close to its business customers. Once a customer becomes large enough, Fastenal installs vending machines and its own personnel on-site. Today, these on-site locations exceed Fastenal's branch count and remain the firm's main focus for expansion. Fastenal acts as a one-stop outsourcing partner for its industrial customers, offering value-added services along with a wide breadth of maintenance, repair, and operations supplies.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: